Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
The objectives of this study were to compare effects of medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg (Cyclofem) and norethisterone enanthate (NET-EN) upon the menstrual pattern and determine changes in lipoprotein parameters after 12 months of use. One-hundred females were included and 87 (45 with Cyclofem and 42 with NET-EN) women completing 12 months were evaluated. Menstrual changes were the leading complaint among users. At the end of 12 months, 20/45 (44.4%) and 18/41 (43.9%) Cyclofem and NET-EN users, respectively, had normal menstrual pattern. Irregular and infrequent bleeding were the two most important changes that occurred. The discontinuation rate at 12 months due to menstrual disturbances did not show any significant differences between the two preparations, but showed lower incidence compared to other studies. Total cholesterol, high-density, low-density and very low-density lipoprotein cholesterol and triglyceride levels decreased at 12 months in both groups and these changes were statistically significant.
Canto de Cetina
Thelma E
TE
Dr. Hideyo Noguchi Biomedical Research Centre, University of Yucatán, Yucatán, México, Mexico. tcetina@tunku.uady.mx
Luna
Manuel Ordoñez
MO
Cetina Canto
José Antonio
JA
Bassol
Susana
S
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000378:metabolism; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008055:Lipids / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D008599:Menstruation Disturbances / Q000139:chemically induced* / Q000517:prevention & control; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D008055:Lipids; D004958:Estradiol; C034528:CycloProvera; C007630:estradiol 17 beta-cypionate; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; C024319:norethindrone enanthate; D009640:Norethindrone